Mineralys Therapeutics presented late-breaking proteomic data at ENDO 2026 showing that lorundrostat, its investigational aldosterone synthase inhibitor, was associated with significant reductions in heart failure risk biomarkers among participants with uncontrolled hypertension. The findings, drawn from a proteomic sub-analysis of an existing clinical dataset, add a mechanistically distinct layer to the compound's cardiovascular evidence base and are likely to draw attention from researchers and formulators tracking biomarker-validated ingredients in the cardiometabolic space.
Aldosterone synthase inhibition represents a targeted mechanism for addressing the renin-angiotensin-aldosterone system (RAAS), a well-characterized pathway in blood pressure regulation and cardiac remodeling. By suppressing aldosterone production at its enzymatic source, lorundrostat is designed to reduce downstream effects including fluid retention, fibrosis signaling, and ventricular stress — biological processes that correspond directly to the heart failure risk biomarkers flagged in the proteomic analysis. While lorundrostat is a pharmaceutical candidate rather than a finished supplement formulation, the proteomic methodology used to detect these clinical endpoints is increasingly informing how the nutraceutical sector validates structure-function claims for cardiometabolic ingredients such as aged garlic extract, CoQ10, and magnesium glycinate.
The broader cardiometabolic supplement category remains one of the fastest-growing segments in functional nutrition, with consumer demand for clinically substantiated heart-health ingredients rising in tandem with hypertension prevalence in aging demographics. Brands operating in this space — particularly those seeking double-blind, placebo-controlled trial data to underpin structure-function claims — are watching pharmaceutical-grade biomarker research closely, as peer-reviewed proteomic endpoints increasingly set the evidentiary bar that retail buyers and regulatory reviewers expect. Coverage of ingredient-level cardiovascular evidence, including magnesium's role in blood pressure management and CoQ10 formulation advances, reflects how quickly this standard is migrating from pharma into the supplement aisle.
Mineralys has not announced nutraceutical licensing, white-label, or co-manufacturing arrangements tied to this mechanism. However, the ENDO 2026 presentation signals growing scientific momentum around aldosterone pathway modulation as a validated cardiovascular target, and ingredient suppliers developing botanical or mineral-based RAAS-supportive compounds may find the proteomic framework a useful template for structuring their own clinical endpoint packages. Operators building out science-forward cardiometabolic SKUs should monitor this data as the peer-reviewed publication cycle progresses.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.